Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

362P - CYBERNEO trial: Update of results at 14 years of follow-up

Date

21 Oct 2023

Session

Poster session 03

Topics

Radiation Oncology

Tumour Site

Breast Cancer

Presenters

Syrine Ben Dhia

Citation

Annals of Oncology (2023) 34 (suppl_2): S325-S333. 10.1016/S0923-7534(23)01259-0

Authors

S. Ben Dhia1, R. schiappa2, J. Gal3, J. Ferrero4, P. Bahadoran5, C. Chapellier6, P. bondiau7

Author affiliations

  • 1 Radiation Oncology, Antoine lacassagne center, 06300 - Nice/FR
  • 2 Department Of Epidemiology, Biostatistics And Data, Centre Anticancer Antoine Lacassagne, 06189 - Nice/FR
  • 3 Biostatistics Unit, Centre Anticancer Antoine Lacassagne, 06189 - Nice/FR
  • 4 Medical Oncology, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 5 Dermatology, CHU Nice - Hopital Pasteur, 06001 - Nice/FR
  • 6 Radiology, Centre Antoine Lacassagne ( CLCC), 0600 - Nice/FR
  • 7 Radiation Oncologie, Centre Antoine Lacassagne ( CLCC), 0600 - Nice/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 362P

Background

The purpose of the phase I “CYBERNEO” trial was to define the efficacy of the CyberKnife®(CK) for locally advanced (stage III) breast tumors combined to a neo-adjuvant treatment with chemotherapy for patients for whom a conservative surgery could not be considered at the onset. Neoadjuvant chemotherapy (NAC) consisted of 6 cycles: 3 cycles of docetaxel and 3 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC). CK was performed during the second cycle of chemotherapy. Breast surgery was performed six to eight weeks later and conventional breast irradiation without boost, afterwards. The main objective was to define the maximum tolerated dose of hypofractionated radiotherapy concurrent with NAC.We present an updated survival data for patients included in this trial and we evaluate the late toxicities of this combination.

Methods

We updated the survival data of 25 patients treated for a stage III breast cancer between 2007 and 2009 at the Antoine Lacassagne Center in Nice and included in the CYBERNEO trial by recording late toxicities and esthetic results.

Results

With a median follow-up of 12 years, 95% CI [10-14], 19 patients (76%) were in remission, 1 patient had a controlled axillary lymph node relapse (4%) band 5 patients (20%) died due to metastatic progression within a median of 5 years after treatment (min: 1, max: 9). Nine patients (36%) had a complete histological response (pCR). The highest percentage of pCR was in the group of patients treated in the 4th stage (28.5 Gy in 4 fractions). Overall survival at 14 years was 71%, 95% CI [53%-94%]. Two patients developed chronic radiation toxicity during follow-up with a fibrosis (8%), of which one was in the 4th stage and one in the 5th stage (31.5 Gy). Three patients (12%) had a change of prosthesis after treatment which for one patient was 24 months after the end of support.

Conclusions

The updated results of the CYBERNEO trial with 14 years of follow-up confirm the satisfactory results in terms of local control with an excellent long-term safety profile.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.